These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32640842)

  • 1. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study.
    Bode BW; Garg SK; Norwood P; Morales C; Hardy T; Liu R; Ignaut D
    Diabetes Technol Ther; 2021 Jan; 23(1):41-50. PubMed ID: 32640842
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.
    Warren M; Bode B; Cho JI; Liu R; Tobian J; Hardy T; Chigutsa F; Phillip M; Horowitz B; Ignaut D
    Diabetes Obes Metab; 2021 Jul; 23(7):1552-1561. PubMed ID: 33687783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System.
    Bode B; Carlson A; Liu R; Hardy T; Bergenstal R; Boyd J; Morrett S; Ignaut D
    Diabetes Technol Ther; 2021 Dec; 23(12):828-836. PubMed ID: 34270335
    [No Abstract]   [Full Text] [Related]  

  • 4. Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
    Leohr J; Dellva MA; LaBell E; Coutant DE; Arrubla J; Plum-Mörschel L; Zijlstra E; Fukuda T; Hardy T
    Diabetes Obes Metab; 2024 Jan; 26(1):215-223. PubMed ID: 37814517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.
    Blevins T; Zhang Q; Frias JP; Jinnouchi H; Chang AM;
    Diabetes Care; 2020 Dec; 43(12):2991-2998. PubMed ID: 32616612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy.
    Malecki MT; Cao D; Liu R; Hardy T; Bode B; Bergenstal RM; Bue-Valleskey J
    Diabetes Technol Ther; 2020 Nov; 22(11):853-860. PubMed ID: 32453647
    [No Abstract]   [Full Text] [Related]  

  • 7. Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog
    Shiramoto M; Nasu R; Oura T; Imori M; Ohwaki K
    J Diabetes Investig; 2020 May; 11(3):672-680. PubMed ID: 31816193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog
    Linnebjerg H; Zhang Q; LaBell E; Dellva MA; Coutant DE; Hövelmann U; Plum-Mörschel L; Herbrand T; Leohr J
    Clin Pharmacokinet; 2020 Dec; 59(12):1589-1599. PubMed ID: 32468447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog
    Leohr J; Dellva MA; Coutant DE; LaBell E; Heise T; Andersen G; Zijlstra E; Hermanski L; Nosek L; Linnebjerg H
    Clin Pharmacokinet; 2020 Dec; 59(12):1601-1610. PubMed ID: 32468448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China.
    Yuan L; Luo Y; Luo Y; Ding B; Zhang P; Ma J; Wu J
    Front Endocrinol (Lausanne); 2024; 15():1364585. PubMed ID: 38774225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.
    Kazda C; Leohr J; Liu R; Reddy S; Dellva MA; Loh MT; Hardy T; Plum-Mörschel L
    Diabetes Obes Metab; 2022 Feb; 24(2):196-203. PubMed ID: 34595812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
    Thrasher J; Surks H; Nowotny I; Pierre S; Rotthaeuser B; Wernicke-Panten K; Garg S
    J Diabetes Sci Technol; 2018 May; 12(3):680-686. PubMed ID: 29359575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis.
    Jinnouchi H; Imori M; Nishiyama H; Imaoka T
    Diabetes Ther; 2020 Sep; 11(9):2075-2088. PubMed ID: 32728833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
    Leohr J; Kazda C; Liu R; Reddy S; Dellva MA; Matzopoulos M; Loh MT; Hardy T; Klein O; Kapitza C
    Diabetes Obes Metab; 2022 Feb; 24(2):187-195. PubMed ID: 34605142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study.
    Klaff L; Cao D; Dellva MA; Tobian J; Miura J; Dahl D; Lucas J; Bue-Valleskey J
    Diabetes Obes Metab; 2020 Oct; 22(10):1799-1807. PubMed ID: 32488923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial.
    Wadwa RP; Laffel LM; Franco DR; Dellva MA; Knights AW; Pollom RK
    Diabetes Obes Metab; 2023 Jan; 25(1):89-97. PubMed ID: 36054737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
    Leohr J; Dellva MA; LaBell E; Coutant DE; Klein O; Plum-Moerschel L; Zijlstra E; Linnebjerg H
    Clin Ther; 2020 Sep; 42(9):1762-1777.e4. PubMed ID: 32900535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension.
    Bue-Valleskey J; Klaff L; Cho JI; Dellva MA; Schloot NC; Tobian J; Miura J; Dahl D
    Diabetes Ther; 2021 Feb; 12(2):569-580. PubMed ID: 33458803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus.
    Aronson R; Biester T; Leohr J; Pollom R; Linnebjerg H; LaBell ES; Zhang Q; Coutant DE; Danne T
    Diabetes Obes Metab; 2023 Jul; 25(7):1964-1972. PubMed ID: 36974352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes.
    Levy CJ; Bailey R; Laffel LM; Forlenza G; DiMeglio LA; Hughes MS; Brown SA; Aleppo G; Bhargava A; Shah VN; Clements MA; Kipnes M; Bruggeman B; Daniels M; Rodriguez H; Calhoun P; Lum JW; Sasson-Katchalski R; Pinsker JE; Pollom R; Beck RW;
    Diabetes Technol Ther; 2024 Sep; 26(9):652-660. PubMed ID: 38696672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.